

Clinical trials of All mechanism for melanoma in ipilumab refractory

TrialResults-center www.trialresultscenter.org

1 anti-PD-1 antibody

Trial	Treatments	Patients	Trials design and methods
pembrolizumab 2mg/kg vs pembrolizumab 10mg/kg			
KEYNOTE-001 , 2014 [NCT01295827] n=89/84 follow-up:	intravenous pembrolizumab at 2 mg/kg every 3 weeks versus intravenous pembrolizumab at 10 mg/kg every 3 weeks	patients (aged 18 years) with advanced melanoma whose disease had progressed after at least two ipilimumab doses	open-label

References

KEYNOTE-001, 2014:

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Ellassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17 [25034862]

[10.1016/j.ejca.2015.06.072](https://doi.org/10.1016/j.ejca.2015.06.072)

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.